First-quarter sales were up 11%, but future growth is less certain.
News & Analysis: Biogen
BIIB earnings call for the period ending March 31, 2019.
These two drug stocks have been the industry's biggest losers this year. Which is the better buy now?
Sometimes opportunity comes in the shape of trouble.
Which stock wins in a battle of two big biotechs?
The biotech giant's most important drug is under a microscope and it doesn't look pretty.
The drugmaker has $4.9 billion in the bank.
The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.
The clinical-stage gene therapy company got some love from biotech giant Biogen last month.
The Swiss pharmaceutical company halted its trial of aducanumab because it wasn't helping patients. But it could still help researchers.